
CIQ
CAS No. 486427-17-2
CIQ( —— )
Catalog No. M26651 CAS No. 486427-17-2
CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit. EC50 value: 2.7 μM for NR2C and 2.8 μM for NR2D.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 42 | Get Quote |
![]() ![]() |
5MG | 69 | Get Quote |
![]() ![]() |
10MG | 114 | Get Quote |
![]() ![]() |
25MG | 222 | Get Quote |
![]() ![]() |
50MG | 331 | Get Quote |
![]() ![]() |
100MG | 489 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCIQ
-
NoteResearch use only, not for human use.
-
Brief DescriptionCIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit. EC50 value: 2.7 μM for NR2C and 2.8 μM for NR2D.
-
DescriptionCIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit. EC50 value: 2.7 μM for NR2C and 2.8 μM for NR2D.(In Vitro):CIQ reduces associated behaviours in schizophrenia models and potentially enhances dopamine release in Parkinson's disease models. NMDA receptor CIQ increases channel opening frequency of recombinant NR2Cor NR2D containing receptors by two-fold (EC50 = 2.7 and 2.8 μM, respectively). It has no effect on NR2A or NR2B subtypes. CIQ does not alter the EC50 values for glutamate or glycine on channel opening. CIQ increases channel opening efficiency and enhances NMDA receptor responses.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetNMDAR
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number486427-17-2
-
Formula Weight467.95
-
Molecular FormulaC26H26ClNO5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 50 mg/mL (106.85 mM)
-
SMILESCOc1ccc(OCC2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Takahashi R, et al. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary. PLoS One. 2016 Mar 17;11(3):e0151050.
molnova catalog



related products
-
Aptiganel
Aptiganel (CNS-1102) is a non-competitive NMDA antagonist, a peptide that may be used to study acute ischemic stroke.
-
(RS)-(Tetrazol-5-yl)...
(RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine) is an effective and selective N-methyl-D-aspartate receptor agonist.
-
UBP551
UBP551 is a potent and selective NMDA receptors modulator.